open access

Vol 70, No 5 (2019)
REVIEWS — Postgraduate Education
Published online: 2019-10-25
Submitted: 2019-04-16
Accepted: 2019-04-29
Get Citation

Pituitary tumours in MEN1 syndrome — the new insight into the diagnosis and treatment

Damian Rogoziński, Aleksandra Gilis-Januszewska, Anna Skalniak, Łukasz Kluczyński, Jacek Pantofliński, Alicja Hubalewska-Dydejczyk
DOI: 10.5603/EP.a2019.0026
·
Pubmed: 31681967
·
Endokrynologia Polska 2019;70(5):445-452.

open access

Vol 70, No 5 (2019)
REVIEWS — Postgraduate Education
Published online: 2019-10-25
Submitted: 2019-04-16
Accepted: 2019-04-29

Abstract

Pituitary tumours are a common pathology affecting 15–20% of the population. Only about 1‰ of adenomas are clinically manifested; among them, about two/thirds are hormonally active, most often secreting prolactin or growth hormone. Pituitary tumours are mainly an isolated pathology, without any genetic background. However, the latest studies pay special attention to the possibility of developing an adenoma as a result of genetic mutation. Among pituitary adenomas, the leading group of genetically determined lesions is related to a mutation in AIP or MEN1, followed by PRKAR1A, GRP101, DICER, and SDHx. The genetic basis of these pituitary tumours is related to positive family history, young age of the patient, aggressive clinical process, and resistance to treatment. Pituitary tumours occur in over 40% of patients with MEN1 syndrome — often in women, they are more than 1 cm in diameter, and secrete prolactin. They are usually diagnosed in the fourth decade of life and show a worse response to pharmacotherapy than sporadic ones. Confirmation of the genetic background of the pituitary tumour implies measurable implications; it might help to direct the diagnosis in patients’ family members, partially predict the development of the disease, and, above all, extend patients’ life expectancy. 

Abstract

Pituitary tumours are a common pathology affecting 15–20% of the population. Only about 1‰ of adenomas are clinically manifested; among them, about two/thirds are hormonally active, most often secreting prolactin or growth hormone. Pituitary tumours are mainly an isolated pathology, without any genetic background. However, the latest studies pay special attention to the possibility of developing an adenoma as a result of genetic mutation. Among pituitary adenomas, the leading group of genetically determined lesions is related to a mutation in AIP or MEN1, followed by PRKAR1A, GRP101, DICER, and SDHx. The genetic basis of these pituitary tumours is related to positive family history, young age of the patient, aggressive clinical process, and resistance to treatment. Pituitary tumours occur in over 40% of patients with MEN1 syndrome — often in women, they are more than 1 cm in diameter, and secrete prolactin. They are usually diagnosed in the fourth decade of life and show a worse response to pharmacotherapy than sporadic ones. Confirmation of the genetic background of the pituitary tumour implies measurable implications; it might help to direct the diagnosis in patients’ family members, partially predict the development of the disease, and, above all, extend patients’ life expectancy. 

Get Citation

Keywords

pituitary tumours; genetic; MEN1 syndrome; diagnostic; treatment

About this article
Title

Pituitary tumours in MEN1 syndrome — the new insight into the diagnosis and treatment

Journal

Endokrynologia Polska

Issue

Vol 70, No 5 (2019)

Pages

445-452

Published online

2019-10-25

DOI

10.5603/EP.a2019.0026

Pubmed

31681967

Bibliographic record

Endokrynologia Polska 2019;70(5):445-452.

Keywords

pituitary tumours
genetic
MEN1 syndrome
diagnostic
treatment

Authors

Damian Rogoziński
Aleksandra Gilis-Januszewska
Anna Skalniak
Łukasz Kluczyński
Jacek Pantofliński
Alicja Hubalewska-Dydejczyk

References (55)
  1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101(3): 613–619.
  2. Newey PJ, Gorvin CM, Cleland SJ. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013; 369(21): 2012–2020.
  3. Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2): 273–288.
  4. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010; 72(3): 377–382.
  5. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006; 91(12): 4769–4775.
  6. Caimari F, Korbonits M. Novel Genetic Causes of Pituitary Adenomas. Clin Cancer Res. 2016; 22(20): 5030–5042.
  7. Marques P, Korbonits M. Genetic Aspects of Pituitary Adenomas. Endocrinol Metab Clin North Am. 2017; 46(2): 335–374.
  8. Falchetti A, Marini F, Luzi E, et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009; 11(12): 825–835.
  9. Syro LV, Scheithauer BW, Kovacs K, et al. Pituitary tumors in patients with MEN1 syndrome. Clinics (Sao Paulo). 2012; 67(Suppl 1): 43–48.
  10. Underdahl LO, Woolner LB, Black BM. Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved. J Clin Endocrinol Metab. 1953; 13(1): 20–47.
  11. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954; 16(3): 363–371.
  12. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997; 276(5311): 404–407.
  13. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010; 24(3): 355–370.
  14. Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9): 2990–3011.
  15. Corbetta S, Pizzocaro A, Peracchi M, et al. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf). 1997; 47(5): 507–512.
  16. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12): 5658–5671.
  17. Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000; 85(12): 4776–4780.
  18. Falchetti A. Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how. F1000 Med Rep. 2010; 2.
  19. Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007; 67(4): 613–622.
  20. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008; 29(1): 22–32.
  21. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998; 62(2): 232–244.
  22. Turner JJO, Leotlela PD, Pannett AAJ, et al. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2002; 87(6): 2688–2693.
  23. Starker LF, Akerström T, Long WD, et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012; 3(1–2): 44–51.
  24. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008; 113(7 Suppl): 1807–1843.
  25. Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178(1): G1–G24.
  26. Skalniak A, Sokołowski G, Jabrocka-Hybel A, et al. A novel in-frame deletion in MEN1 (p.Ala416del) causes familial multiple endocrine neoplasia type 1 with an aggressive phenotype and unexpected inheritance pattern. Mol Med Rep. 2016; 14(3): 2061–2066.
  27. Multiple Endocrine Neoplasia Type 1 (MEN1) Workup: Approach Considerations, Laboratory Studies, Imaging Studies. https:/emedicine.medscape.com/article/126438-workup (February 25, 2019).
  28. MEN1 screening protocol (Published January 2017). http://www.edinburghdiabetes.com/s/2017-02-01-MEN1-Screening.docx.
  29. Drug Safety and Availability — FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) (Published July 25, 2015)). https://www.fda.gov/Drugs/DrugSafety/ucm455386.htm (Accessed February 25, 2019.).
  30. Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents — current status. Neuroradiology. 2016; 58(5): 433–441.
  31. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015; 100(4): 1568–1577.
  32. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010; 34(2): 249–255.
  33. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(s2): 2–8.
  34. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006; 244(1): 61–70.
  35. Norton JA, Fraker DL, Alexander HR, et al. Surgery to Cure the Zollinger–Ellison Syndrome. N Engl J Med. 1999; 341(9): 635–644.
  36. Waldmann J, López CL, Langer P, et al. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg. 2010; 97(10): 1528–1534.
  37. Schreinemakers JMJ, Pieterman CRC, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011; 35(9): 1993–2005.
  38. Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007; 21(1): 87–109.
  39. Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002; 87(2): 457–465.
  40. Wilson-Hardy classification. NeuroMind.cc. https://www.neuromind.cc/tumor/wilson-hardy-classification/ (March 5, 2019).
  41. Trouillas J, Labat-Moleur F, Sturm N, et al. Groupe d'études des Tumeurs Endocrines. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008; 32(4): 534–543.
  42. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery. 1998; 124(6): 1106–1114.
  43. Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord. 2008; 9(1): 1–11.
  44. Saeger W, Petersenn S, Schöfl C, et al. Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification. Endocr Pathol. 2016; 27(2): 115–122.
  45. Garby L, Caron P, Claustrat F, et al. GTE Group. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab. 2012; 97(6): 2093–2104.
  46. Saleem TF, Santhanam P, Hamoudeh E, et al. Acromegaly caused by growth hormone releasing hormone (GHRH) secreting tumor in multiple endocrine neoplasia (MEN-1). W V Med J. 2012; 108(2): 26–30.
  47. Berger G, Trouillas J, Bloch B, et al. Multihormonal carcinoid tumor of the pancreas. Secreting growth hormone-releasing factor as a cause of acromegaly. Cancer. 1984; 54(10): 2097–2108, doi: 10.1002/1097-0142(19841115)54:10<2097::AID-CNCR2820541009>3.0.CO;2-X.
  48. Stelmachowska-Banaś M, Głogowski M, Vasiljevic A, et al. Ectopic acromegaly due to growth hormone-releasing hormone secretion from bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. Pol Arch Intern Med. 2019; 129(3): 208–210.
  49. Bolanowski M, Schopohl J, Marciniak M, et al. Acromegaly due to GHRH-secreting large bronchial carcinoid. Complete recovery following tumor surgery. Exp Clin Endocrinol Diabetes. 2002; 110(4): 188–192.
  50. Benito M, Asa SL, Livolsi VA, et al. Gonadotroph tumor associated with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2005; 90(1): 570–574.
  51. Gordon MV, Varma D, McLean CA, et al. Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1). Clin Endocrinol (Oxf). 2007; 66(1): 150–152.
  52. Scheithauer BW, Kovacs K, Nose V, et al. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum Pathol. 2009; 40(2): 270–278.
  53. Gilis-Januszewska A, Wilusz M, Pantofliński J, et al. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review. Endokrynol Pol. 2018; 69(3): 306–312.
  54. de Laat JM, Dekkers OM, Pieterman CRC, et al. Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab. 2015; 100(9): 3288–3296.
  55. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985; 60(4): 698–705.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl